|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
IL290809B2
(en)
|
2016-11-01 |
2024-01-01 |
Arvinas Operations Inc |
Tau-protein targeting protacs and associated methods of use
|
|
EP4717317A2
(en)
|
2017-06-20 |
2026-04-01 |
C4 Therapeutics, Inc. |
N/o-linked degrons and degronimers for protein degradation
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
|
|
JP2021519337A
(ja)
|
2018-03-26 |
2021-08-10 |
シー４ セラピューティクス， インコーポレイテッド |
Ｉｋａｒｏｓの分解のためのセレブロン結合剤
|
|
CN119751456A
(zh)
|
2018-04-16 |
2025-04-04 |
C4医药公司 |
螺环化合物
|
|
WO2019222272A1
(en)
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
JP2021527137A
(ja)
|
2018-06-13 |
2021-10-11 |
アンフィスタ セラピューティクス リミテッド |
Ｒｐｎ１１を標的化するための二機能性分子
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
WO2020176983A1
(en)
|
2019-03-01 |
2020-09-10 |
Ontario Institute For Cancer Research (Oicr) |
Amide-based proteolysis modulators of b-rapidly accelerated fibrosarcoma (braf) and associated uses
|
|
CN120172958A
(zh)
|
2019-04-12 |
2025-06-20 |
C4医药公司 |
Ikaros和aiolos的三环降解物
|
|
CN113811333B
(zh)
|
2019-05-14 |
2024-03-12 |
诺维逊生物股份有限公司 |
靶向抗癌核激素受体的化合物
|
|
WO2020252398A1
(en)
*
|
2019-06-12 |
2020-12-17 |
Northwestern University |
Proteolysis-targeting protacs inducing degradation of c-mic protein
|
|
CN119954801A
(zh)
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
IL320609A
(en)
*
|
2019-08-26 |
2025-07-01 |
Arvinas Operations Inc |
Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
|
|
WO2021097046A1
(en)
|
2019-11-13 |
2021-05-20 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
AU2020392427B2
(en)
|
2019-11-27 |
2024-03-07 |
Captor Therapeutics S.A. |
Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
|
|
JP2023508891A
(ja)
*
|
2019-12-17 |
2023-03-06 |
オリオニス バイオサイエンシズ，インコーポレイテッド |
タンパク質の動員および／または分解のための二機能性剤
|
|
JP7682181B2
(ja)
*
|
2019-12-18 |
2025-05-23 |
ノバルティス アーゲー |
３－（５－メトキシ－１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
|
|
CA3165168A1
(en)
*
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
BR112022011827A2
(pt)
|
2019-12-20 |
2022-08-30 |
C4 Therapeutics Inc |
Composto, composição farmacêutica, uso de um composto, métodos para tratamento ou profilaxia de câncer e para tratar um paciente com um distúrbio mediado por receptor do fator de crescimento epidérmico, e, invenção
|
|
AU2021231898A1
(en)
|
2020-03-05 |
2022-10-27 |
C4 Therapeutics, Inc. |
Compounds for targeted degradation of BRD9
|
|
US20230123104A1
(en)
*
|
2020-03-06 |
2023-04-20 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Crystal of tricyclic compound acting on crbn protein and preparation method therefor
|
|
WO2021185291A1
(zh)
*
|
2020-03-17 |
2021-09-23 |
南京明德新药研发有限公司 |
蛋白降解调节剂与其使用方法
|
|
KR20230004511A
(ko)
|
2020-03-21 |
2023-01-06 |
아비나스 오퍼레이션스, 인코포레이티드 |
인다졸계 화합물 및 관련된 사용 방법
|
|
EP4121167A1
(en)
|
2020-03-21 |
2023-01-25 |
Arvinas Operations, Inc. |
Selective modulators of mutant lrrk2 proteolysis and associated methods of use
|
|
CN113582974B
(zh)
*
|
2020-04-30 |
2022-05-17 |
江西济民可信集团有限公司 |
一类作为蛋白降解剂的化合物及其制备方法和医药用途
|
|
WO2021255212A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Braf degraders
|
|
EP4174059A4
(en)
*
|
2020-06-28 |
2024-07-03 |
Medshine Discovery Inc. |
INDAZOLE FUSED CYCLIC COMPOUND
|
|
WO2022007903A1
(zh)
*
|
2020-07-09 |
2022-01-13 |
四川海思科制药有限公司 |
一种能够抑制并降解雄激素受体的化合物及其药物组合物和药学上的应用
|
|
CN114341128B
(zh)
*
|
2020-07-24 |
2024-06-25 |
恩瑞生物医药科技（上海）有限公司 |
双功能蛋白降解靶向嵌合体类化合物及其制备方法和医药用途
|
|
EP4192458A4
(en)
|
2020-08-05 |
2024-09-04 |
C4 Therapeutics, Inc. |
COMPOUNDS FOR TARGETED DEGRADATION OF RET
|
|
WO2022048605A1
(zh)
*
|
2020-09-04 |
2022-03-10 |
南昌奥瑞药业有限公司 |
一种杂环化合物、其制备方法、中间体、组合物以及应用
|
|
CN114262319B
(zh)
*
|
2020-12-01 |
2023-05-05 |
南昌奥瑞药业有限公司 |
一类双功能分子、其制备方法及其应用
|
|
WO2022120355A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead degraders and uses thereof
|
|
CN116744925A
(zh)
*
|
2020-12-14 |
2023-09-12 |
阿尔维纳斯运营股份有限公司 |
用四氢萘衍生物作为雌激素受体降解剂治疗乳腺癌的方法
|
|
CN112679338A
(zh)
*
|
2020-12-28 |
2021-04-20 |
丽珠集团新北江制药股份有限公司 |
一种制备噁唑啉杀虫剂阿福拉纳中间体的方法
|
|
CN112707809B
(zh)
*
|
2020-12-30 |
2023-08-29 |
丽珠集团新北江制药股份有限公司 |
一种制备噁唑啉杀虫剂氟雷拉纳中间体的方法
|
|
JP2024504932A
(ja)
|
2021-01-13 |
2024-02-02 |
モンテ ローザ セラピューティクス， インコーポレイテッド |
イソインドリノン化合物
|
|
EP4289841A4
(en)
*
|
2021-02-04 |
2025-02-19 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Benzo seven-membered ring bifunctional compound and application thereof
|
|
WO2022198112A1
(en)
|
2021-03-19 |
2022-09-22 |
Arvinas Operations, Inc. |
Indazole based compounds and associated methods of use
|
|
KR20230160299A
(ko)
|
2021-03-23 |
2023-11-23 |
누베이션 바이오 인크. |
항암 핵 호르몬 수용체 표적화 화합물
|
|
MX2023011166A
(es)
*
|
2021-03-29 |
2023-09-29 |
Jiangsu Hengrui Pharmaceuticals Co Ltd |
Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina.
|
|
CN115141179B
(zh)
*
|
2021-03-31 |
2024-09-13 |
江苏恒瑞医药股份有限公司 |
一种新型苯并杂环基类衍生物、其制备方法及其在医药上的应用
|
|
US12006314B2
(en)
|
2021-05-03 |
2024-06-11 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20240017814A
(ko)
|
2021-05-05 |
2024-02-08 |
바이오젠 엠에이 인코포레이티드 |
브루톤 티로신 키나제의 분해를 표적으로 하는 화합물
|
|
AU2022271290A1
(en)
|
2021-05-07 |
2023-11-23 |
Kymera Therapeutics, Inc. |
Cdk2 degraders and uses thereof
|
|
WO2022261250A1
(en)
|
2021-06-08 |
2022-12-15 |
C4 Therapeutics, Inc. |
Therapeutics for the degradation of mutant braf
|
|
US20250129047A1
(en)
|
2021-07-04 |
2025-04-24 |
Newave Pharmaceutical Inc. |
Isoquinoline derivatives as mutant egfr modulators and uses thereof
|
|
KR20240035526A
(ko)
|
2021-07-07 |
2024-03-15 |
바이오젠 엠에이 인코포레이티드 |
Irak4 단백질의 분해를 표적하는 화합물
|
|
WO2023283372A1
(en)
|
2021-07-07 |
2023-01-12 |
Biogen Ma Inc. |
Compounds for targeting degradation of irak4 proteins
|
|
KR20240035820A
(ko)
|
2021-07-09 |
2024-03-18 |
플렉시움 인코포레이티드 |
Ikzf2를 조절하는 아릴 화합물 및 약학 조성물
|
|
EP4377296A1
(en)
*
|
2021-07-26 |
2024-06-05 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound
|
|
US20250171417A1
(en)
*
|
2021-08-11 |
2025-05-29 |
Xizang Haisco Pharmaceutical Co., Ltd. |
Heterocyclic derivative, and composition and pharmaceutical use thereof
|
|
CN115746058A
(zh)
*
|
2021-09-03 |
2023-03-07 |
南京知和医药科技有限公司 |
一种多环化合物在制备抗肿瘤药物方面的用途
|
|
AU2022370021B2
(en)
*
|
2021-10-22 |
2026-04-16 |
Gluetacs Therapeutics (Shanghai) Co., Ltd. |
Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications
|
|
EP4452415B1
(en)
|
2021-12-22 |
2026-02-25 |
Gilead Sciences, Inc. |
Ikaros zinc finger family degraders and uses thereof
|
|
CN114516810B
(zh)
*
|
2022-01-18 |
2023-12-26 |
浙江奥翔药业股份有限公司 |
制备药物中间体2-氨基-4-羟基苯甲酸的方法
|
|
CN114085213B
(zh)
*
|
2022-01-20 |
2022-03-25 |
苏州国匡医药科技有限公司 |
一种arv-471的制备方法
|
|
CA3253296A1
(en)
|
2022-03-17 |
2023-09-21 |
Gilead Sciences, Inc. |
Zinc Finger Degradation Agents of the Ikaros Family and Their Uses
|
|
JP2025523393A
(ja)
|
2022-06-06 |
2025-07-23 |
シーフォー セラピューティクス， インコーポレイテッド |
二環式置換グルタルイミドセレブロンバインダー
|
|
CN117229286A
(zh)
*
|
2022-06-14 |
2023-12-15 |
海创药业股份有限公司 |
一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途
|
|
TW202417425A
(zh)
|
2022-06-27 |
2024-05-01 |
美商傳達治療有限公司 |
雌激素受體α降解劑及其使用方法
|
|
WO2024006776A1
(en)
|
2022-06-27 |
2024-01-04 |
Relay Therapeutics, Inc. |
Estrogen receptor alpha degraders and medical use thereof
|
|
AU2023300784A1
(en)
*
|
2022-06-30 |
2025-01-02 |
Anhorn Medicines Co., Ltd. |
Bifunctional compound and pharmaceutical composition comprising the bifunctional compound, and method for treating androgen receptor related diseases by using the same
|
|
KR20250047743A
(ko)
*
|
2022-07-12 |
2025-04-04 |
리젠츠 오브 더 유니버시티 오브 미시간 |
에스트로겐 수용체 분해제로서의 테트라하이드로나프탈렌 유도체
|
|
JP2025528223A
(ja)
|
2022-08-17 |
2025-08-26 |
コリア リサーチ インスティテュート オブ ケミカル テクノロジー |
Ｃｄｋ２及び／又はｃｄｋ９の抑制又は分解用化合物及びこれらの医薬用途
|
|
CN115403561B
(zh)
*
|
2022-08-22 |
2024-03-08 |
西安交通大学 |
一种基于沙利度胺类似物的细胞内自组装蛋白降解剂及其制备方法和应用
|
|
WO2024054955A1
(en)
*
|
2022-09-08 |
2024-03-14 |
Halda Therapeutics Opco, Inc. |
Heterobifunctional compounds and methods of treating disease
|
|
US20260098027A1
(en)
*
|
2022-09-29 |
2026-04-09 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutically acceptable salt and crystal form of tetrahydronaphthalene derivative, and preparation method
|
|
WO2024067793A1
(zh)
*
|
2022-09-29 |
2024-04-04 |
海南先声再明医药股份有限公司 |
一类稠环化合物及其用途
|
|
CN117801051A
(zh)
*
|
2022-09-30 |
2024-04-02 |
苏州德亘生物医药有限公司 |
一类eRF3a靶向蛋白降解机制治疗人类肿瘤的药物
|
|
US20260109715A1
(en)
|
2022-10-03 |
2026-04-23 |
Public University Corporation Yokohama City University |
Imidazopyridine derivatives with bicyclic structure
|
|
CN116751186B
(zh)
*
|
2022-12-23 |
2024-10-18 |
南京知和医药科技有限公司 |
一种雌激素受体调节剂的制备及其用途
|
|
WO2024153025A1
(zh)
*
|
2023-01-16 |
2024-07-25 |
南京明德新药研发有限公司 |
取代的苯并七元环化合物及其应用
|
|
WO2024157953A1
(ja)
|
2023-01-24 |
2024-08-02 |
第一三共株式会社 |
置換ベンゼン化合物
|
|
CN116253719B
(zh)
*
|
2023-03-06 |
2025-04-01 |
苏州国匡医药科技有限公司 |
一种雌激素和雄激素受体双重降解剂及其应用
|
|
US20240374588A1
(en)
|
2023-04-07 |
2024-11-14 |
Astrazeneca Ab |
Irak4 protacs
|
|
WO2024226422A1
(en)
*
|
2023-04-22 |
2024-10-31 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Helicase degraders
|
|
WO2024240858A1
(en)
|
2023-05-23 |
2024-11-28 |
Valerio Therapeutics |
Protac molecules directed against dna damage repair system and uses thereof
|
|
EP4722206A1
(en)
*
|
2023-06-01 |
2026-04-08 |
Haihe Biopharma Co., Ltd. |
Benzo(hetero)cycloalkyl compounds for androgen receptor-dependent diseases
|
|
WO2025006753A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras protein
|
|
WO2025006783A2
(en)
|
2023-06-30 |
2025-01-02 |
Merck Patent Gmbh |
Heterobifunctional compounds for the degradation of kras
|
|
CN119613374A
(zh)
*
|
2023-09-14 |
2025-03-14 |
中国科学院上海药物研究所 |
吲唑酮类化合物、其制备方法、药物组合物及其应用
|
|
AU2024352092A1
(en)
|
2023-09-28 |
2026-04-09 |
Arvinas Operations, Inc. |
Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
|
|
CN121925410A
(zh)
|
2023-09-29 |
2026-04-24 |
第一三共株式会社 |
3-苯基丙胺衍生物
|
|
WO2025081092A1
(en)
*
|
2023-10-12 |
2025-04-17 |
Kolm Therapeutics Inc. |
Bifunctional androgen receptor compounds
|
|
WO2025129172A1
(en)
*
|
2023-12-14 |
2025-06-19 |
The Board Of Trustees Of The Leland Stanford Junior University |
Crbn molecular glue degraders and uses thereof
|
|
WO2025136129A1
(en)
*
|
2023-12-22 |
2025-06-26 |
Captor Therapeutics S.A. |
Targeted protein degradation using bifunctional compounds that bind ubiquitin ligase and target protein kinase c
|
|
TW202543650A
(zh)
|
2024-03-08 |
2025-11-16 |
美商海爾達醫療運營公司 |
異雙官能化合物及其在治療疾病中之用途
|
|
WO2025245032A1
(en)
*
|
2024-05-20 |
2025-11-27 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound
|
|
WO2026060321A1
(en)
|
2024-09-13 |
2026-03-19 |
Olema Pharmaceuticals, Inc. |
Kat6 degrader compounds and method thereof
|
|
GB202414342D0
(en)
*
|
2024-09-30 |
2024-11-13 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|